Cure touted for Hep C
Posted May 26, 2010 10:27 am.
This article is more than 5 years old.
A new Hepatitis C treatment being developed in the U.S. has led to a 75 per cent cure rate, according to the company that makes a new drug.
Vertex Pharmaceuticals claims the results of a new study on Telaprevir came in at the high end of their expectations.
Reuters news service reprots, phase III patients in the study received 3-months of Telaprevir combined with current standard treatment drugs. Three months of standard treatment followed.
75 per cent sustained virologic response, or SVR, which is tantamount to a cure.
That’s compared to a 44 per cent SVR rate for patients who received the current treatment alone.
Telaprevir is expected to become a multi-billion-dollar drug for Vertex if approved by the U.S. Food and Drug Administration.
